This Market Spotlight report covers the Coronary Artery Disease (CAD) market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, probability of success, and 10-year disease prevalence and incidence forecasts, as well as presenting drug-specific revenue forecasts.

Key Takeaways

• Datamonitor Healthcare estimates that in 2021, there were approximately 228.6 million prevalent cases of coronary artery disease worldwide, and forecasts that number to increase to 252.1 million prevalent cases by 2029.
• Datamonitor Healthcare estimates that in 2021, there were approximately 5.3 million incident cases of acute coronary syndrome worldwide, and forecasts that number to increase to 5.8 million incident cases by 2029.
• The approved drugs in the coronary artery disease space target angiotensin converting enzyme, amyloid beta/amyloid plaques, adenosine diphosphate P2Y12 receptor, calcium channel, and coagulation factor X. The majority of marketed drugs are administered via the oral route, with one product being available in an intravenous formulation.
• There are only four industry-sponsored drugs in active clinical development for coronary artery disease, which are all in Phase II. Therapies in development for coronary artery disease target alpha 2 adrenergic receptor, FLAP/5-lipoxygenase activating protein, endothelial lipase, reverse cholesterol transport, and fibroblast growth factor receptor. These drugs are administered via the oral, subcutaneous, and percutaneous catheter/injection routes.
• The only high-impact upcoming event for drugs in the coronary artery disease space is topline Phase IIa trial results for AZD5718.
• The overall likelihood of approval of a Phase I cardiovascular disease asset is 7.1%, and the average probability a drug advances from Phase III is 55%. Drugs, on average, take 10.4 years from Phase I to approval in the cardiovascular space.
• The distribution of clinical trials across Phase I–IV indicates that the majority of trials for coronary artery disease have been in the late phases of development, with 53% of trials in Phase III–IV and 47% in Phase I–II.
• The US has a substantial lead in the number of coronary artery disease clinical trials globally. The UK leads the major European markets, while China has the top spot in Asia.
• Clinical trial activity in the coronary artery disease space is dominated by completed trials. AstraZeneca has the highest number of completed clinical trials for coronary artery disease, with 65 trials.
• AstraZeneca leads industry sponsors with the highest overall number of clinical trials for coronary artery disease.